Images: AP

Once upon a time, Theranos was a promising biotech firm—raising $632 million from 2014-2015. In October 2015, everything changed when the Wall Street Journal published the first of its many exposés that revealed the company’s struggle to develop the blood-testing technology it promised. The Journal’s stories ultimately led to the company’s very ugly public unraveling. A new report published on Monday reveals that Rupert Murdoch, the executive chairman of the Wall Street Journal’s parent company, invested $100 million in Theranos shortly before the paper published its first report.

Theranos, which is currently under criminal investigation, acquired much of its funding “from high-profile private investors who weren’t part of the ecosystem that typically backs startups and could see their stakes wiped out by the blood-testing company’s regulatory and technological troubles,” reports the Wall Street Journal.

Advertisement

Communications conglomerate Cox Enterprises also invested $100 million in the company between 2014 and 2015. Walgreens is now suing Theranos for the $140 million it invested.

On Monday, the Wall Street Journal also reported that another disgruntled Theranos investor, Silicon Valley pioneer Robert Colman, filed a lawsuit against Theranos for “making false and misleading claims about its operations and technology while soliciting money from investors.” The suit is seeking class action status.

Advertisement

Partner Fund Management LP, a San Francisco hedge fund filed a lawsuit, against the company in October, claiming “a series of lies, material misstatements, and omissions, [Theranos and Elizabeth Holmes] engaged in securities fraud and other violations by fraudulently inducing PFM to invest and maintain its investment in the company.”

At this point, you gotta ask yourself: How could it get worse for Theranos? Only the sweet passage of time will tell.

[Wall Street Journal]